Payment overview · 2025
General Payments
$2,665.23
66 reported records · 24 companies
Healthcare provider profile · identity verified
Steven Mercado, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1043615503
Verified facts
What the public records show
CMS Open Payments records show Steven Mercado, M.D. received $2,665.23 in general payments during 2025 across 66 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $358.42 | 13.4% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $316.55 | 11.9% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $252.26 | 9.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $200.03 | 7.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $174.13 | 6.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $158.24 | 5.9% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $153.05 | 5.7% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $146.20 | 5.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.99 | 4.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $124.98 | 4.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $124.36 | 4.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $121.78 | 4.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.44 | 4.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $51.09 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.97 | 1.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.02 | 1.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.14 | 1.2% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $23.63 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.56 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.65 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.99 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.15 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.55 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.05 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,665.23 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $281.54 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $248.20 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $247.66 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $192.54 | 9 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $158.24 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $153.05 | 2 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $146.20 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $124.92 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $124.36 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $121.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $121.44 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $51.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.21 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.93 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.97 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.89 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $7.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 433 | 140 |
| Losartan Potassium | Losartan Potassium | 388 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 238 | 80 |
| Metformin Hcl | Metformin Hcl | 218 | 77 |
| Lisinopril | Lisinopril | 216 | 68 |
| Gabapentin | Gabapentin | 186 | 42 |
| Eliquis | Apixaban | 183 | 30 |
| Meloxicam | Meloxicam | 157 | 58 |
| Jardiance | Empagliflozin | 128 | 39 |
| Omeprazole | Omeprazole | 128 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 38 |
| Sertraline Hcl | Sertraline Hcl | 113 | 24 |
| Prednisone | Prednisone | 110 | 95 |
| Ozempic | Semaglutide | 104 | 26 |
| Trazodone Hcl | Trazodone Hcl | 92 | 33 |
| Azithromycin | Azithromycin | 91 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 19 |
| Glimepiride | Glimepiride | 71 | 26 |
| Carvedilol | Carvedilol | 70 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 54 |
| Famotidine | Famotidine | 59 | 16 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Furosemide | Furosemide | 56 | 24 |
| Ezetimibe | Ezetimibe | 54 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 26 |
| Potassium Chloride | Potassium Chloride | 41 | 21 |
| Spironolactone | Spironolactone | 41 | 14 |
| Simvastatin | Simvastatin | 40 | 13 |
| Tramadol Hcl | Tramadol Hcl | 40 | 15 |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 13 |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 15 |
| Atenolol | Atenolol | 33 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | 11 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 11 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Diazepam | Diazepam | 26 | 12 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,665.23 · 66 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, Dexcom G6 Transmitter, ENTRESTO, EVENITY, FARXIGA, Fluad, Flucelvax, INSPIRE, JARDIANCE, Korlym, LEQVIO, Leqembi, MAKO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, SHINGRIX, Senza, TZIELD, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error